Marketresearchnews

Thursday, 18 April 2019

Global Plasma Fractionation Market Recent Trends, Growth Opportunities, Forecast by Application and Types to 2023

Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.

In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.

Global plasma fractionation market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.

Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.

However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.

Segmentation

The global plasma fractionation market is segmented based on product, application, end user, and region.

The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.

Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.

Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.

In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.

The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.

In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.

Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.

On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Nasal Drug Delivery Market in depth study and analysis published, 2019

Market Scenario

The nasal route administration is experiencing tremendous growth due to its noninvasive nature consequently reducing pain and threat of infections. It allows the patient to self-administer drugs thus not requiring any external help. The high vasculature, high permeability, and low enzymatic environment of nasal cavity are perfectly apt for systemic delivery of drug molecules via nose. There is no risk of drug destruction by hydrogen chloride (HCl) present in the stomach thereby increasing bioavailability which reduces the dosage of the drug. This, in turn, leads to proportional reduction in side effects.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2696

Increasing popularity of over-the-counter nasal drugs such as inhalers for the common cold is also propel the market in an upward manner. Nasal drugs prove to be advantageous for the market, with a plethora of factors like good penetration of the drugs into the nasal cavity, improving patient compliance, rapid absorption, onset of action, and requirement of low dosage.

Segments:

Middle East and Africa Nasal Drug Delivery market has been segmented on the basis of dosage form which comprises of drops, sprays, powder, gels and ointments. On the basis of system, market is segmented into unit dose, multi-dose and metered dose. On the basis of delivery technologies; market is segmented into spray, nebulizers and other. On the basis of therapeutic applications; market is segmented into rhinitis, congestion, vaccinations and others.

Drivers and Restraints

The market for Nasal Drug Delivery is growing remarkably with a consistently good CAGR due to the benefits accompanying nasal drugs. Other driving factors include innovation of drugs which are absorbed easily from the nasal route, innovations in advanced products which allow the delivery of precise doses and also ease of administration. However, the restraints that threaten the growth of the market are irritation of the nasal route and the low dose of the drug that can be delivered as compared to other routes of administration. Other constraints include concurrent low popularity of the route which reduces economies of scale in producing these delivery devices and low awareness. According to an extensive report by Market Research Future (MRFR), the Middle East and Africa Nasal Drug Delivery market is presumed to reach around USD 1.59 billion in 2022 surging at a CAGR of 8.1% from 2017 to 2022. The market was estimated to be worth USD 1 billion in 2015.

Key Players

Novartis AG

Pfizer, Inc.

Sanofi-Aventis

Merck & Co., Inc.

AptarGroup Inc.

Johnson & Johnson Services, Inc.

GlaxoSmithKline plc

Becton Dickson & Company

Regional Analysis

UAE is the largest market for Nasal Drug Delivery in entire Middle East and Africa Nasal Drug Delivery Market closely followed by Egypt. The rest of Africa’s market is growing at a very fast rate due to huge unmet medical needs and growing popularity of nasal route.

Browse Complete 84 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/nasal-drug-delivery-market-2696

Detailed Table of Contents:

Introduction

1.1 Definition

1.2 Scope Of Study

1.2.1 Research Objective

1.2.2 Assumptions & Limitations

1.2.2.1 Assumptions

1.2.2.2 Limitations

1.3 Market Structure

Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

...Continued

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Wednesday, 17 April 2019

Neuroendoscopy Market to show steady growth, 2019

Market Scenario

Neuroendoscopy is characterized as a minimally-invasive surgical procedure which is extensively utilized to remove tumors. The excision occurs via small holes present in the skull, i.e., through the mouth or nose. In neuroendoscopy procedures, a small telescopic device equipped with a high-resolution video camera and an eyepiece is used. This gives the neurosurgeons, an ability to navigate and effectively access the parts of the brain that could not be addressed by traditional surgery. Some of the other advantages of neuroendoscopy include fast recovery, minimal scarring, and others. The increasing prevalence of brain tumors is a major driver for the market growth. According to a study published by the Neuro-Oncology Journal in 2015, the global incidence rate for all types of brain tumors was estimated to be about 10.82 per 100 000 persons. Moreover, the increasing demand for minimally invasive surgical procedures, growing geriatric population, and favorable reimbursement policies are estimated to boost the market during the forecast period. According to the National Institute of Health in 2016, the global geriatric population is estimated to be more than triple from 2015 to 2050, i.e., it is projected to grow from 126.5 in 2015 million and reach 446.6 million by 2050. However, a shortage of physicians and high cost for neuroendoscopy procedures and equipment are projected to restrain the market growth during the forecast period. The Association of American Medical Colleges in 2016 stated that the demand for physicians continued to grow at a higher rate, exceeding the supply. The projected total physician shortfall by 2025 is estimated to be in between 61,700 and 94,700.

Global Neuroendoscopy Market is expected to grow at an approximate CAGR of 5.2% during the forecast period.

Intended Audience

Pharmaceutical Companies
Biotechnological Institutes
Government and Private Laboratories
Research and Development (R&D) Companies
Medical Research Laboratories
Market Research and Consulting Service Providers

Segmentation

The global Neuroendoscopy market is segmented on the basis of product, application, usability, and end-user.

On the basis of products, the market is segmented into rigid neuroendoscopes and flexible neuroendoscopes. The rigid neuroendoscopes segment is sub-segmented into rigid video scopes and rigid fiberscopes. On the basis of application, the market is categorized into transnasal neuroendoscopy, intraventricular neuroendoscopy, and transcranial neuro-endoscopy. On the basis of usability, the market is segmented into reusable neuroendoscopes and disposable neuroendoscopes. On the basis of end-users, the market is segmented into hospitals, clinics, medical research centers, and others.

Regional Analysis

The Americas dominates the global neuroendoscopy market. Factors such as the increasing prevalence of brain tumors, the presence of a well-developed healthcare sector, and huge health care expenditures within the region drive the market growth within the region. Moreover, the presence of key players such as Stryker and Medtronic, besides others and the growing geriatric population within the region fuel the market growth.

Europe stands second in the global neuroendoscopy market due to the increasing demand for minimally invasive surgeries, rising availability of funds for research and development, and a huge patient population. According to the Cancer Research U.K., the total number of new cases for brain tumor was estimated to be about 11,432 in 2015.

Followed by Europe, Asia Pacific stands third in the global neuroendoscopy market. Moreover, the region is projected to be the fastest growing region in the global market. This can be attributed to the presence of developing economies such as China, growing patient population, developing healthcare sector, and increasing per capita healthcare expenditures. Additionally, favorable government policies support the market growth. Medical tourism and rising geriatric population are estimated to fuel the market growth. According to the Indian Brand Equity Foundation, the medical tourism industry in India is estimated to grow rapidly and reach USD 9 billion by 2020.

The Middle East and Africa holds the least share in the global neuroendoscopy market due to the presence of poor economies, stringent government policies, lack of awareness, low per capita income, and poor availability of healthcare services, especially within the African region. A majority of the neuroendoscopy market within the region is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure.

Key players

The key players in the global neuroendoscopy market are KARL STORZ (Germany), B. Braun (Germany), Ackermann Instrumente (Germany), Adeor Medical (Germany), Hangzhou Hawk Optical Electronic Instruments (China), Machida Endoscope (Japan), Tonglu Wanhe Medical Instrument (China), Schindler Endoskopie (Germany), Clarus Medical (U.S.), LocaMed (U.K), Visionsense Corporation (U.S.), Olympus Corporation (Japan), Zeiss International (Germany), Stryker (U.S.), Medtronic (U.S.), and others.

Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/neuroendoscopy-market-5836

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Uterine Sarcoma Market Market Dynamics, Forecast, Analysis and Supply Demand 2019

Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016. Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.

The market for global uterine sarcoma is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.

Key players

Pfizer Inc.
Intas Pharmaceuticals Ltd.
FMC Corporation
Sun Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc.
General Electric Company
Koninklijke Philips N.V.
Siemens Healthcare Private Limited

Segmentation

The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.

On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.

On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.

On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.

Regional Analysis

Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.

America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.

Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population. By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.

The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/uterine-sarcoma-market-5131

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Biological Computers Market 2019–By Identifying the Key Market Segments and Key players holding market share

Market Synopsis of the Global Biological computers Market

Biological computers, also known as DNA computers, are microcomputers designed for their use in the field of medicine. This implantable device can be used for various functions such as monitoring the activities of the body or inducing therapeutic effects. Hardware, software, input, and output are the four major components of a biological computer. These components are made of DNA, RNA and proteins. Biological computers are able to perform mathematical calculations that enable the researcher to construct a system of biosensors. This system of biosensors can detect or target specific types of cells such as cancer cells in the patient’s body.

Rising prevalence of cancer, and increasing demand for DNA or gene chips are some of the major factors driving the growth of this market across the globe. Furthermore, increasing healthcare expenditure and overall growth of the healthcare industry also influence the market growth. Splendid research in the field of oncology also boosts the market.

As per the report of the Centers for Disease Control and Prevention (CDC), in 2014, over 14.1 million of new cancer cases were registered worldwide.

The global biological computers market is expected to grow at a CAGR of 7.1% during the forecast period 2017-2023.

Segments

The global biological computers market is segmented on the basis of component, application, and end user.

On the basis of the component, market is segmented into hardware, software, input, and output.

On the basis of the application, the market is segmented into oncology, molecular genetics, nanobiotechnology, and others.

On the basis of the end user, the market is segmented into pharmaceutical & biotechnology companies, research centers, healthcare it companies, hospital & clinics, and others.

Regional Analysis of the Global Biological Computers Market

The Americas hold the first position in the biological computers market owing to the rising prevalence of cancer in the U.S., and increasing demand for new cancer diagnostic and treatment services. In the Americas, North America is the largest market owing to the presence of key players in the healthcare IT industry.

Europe is the second largest market for biological computers. In Europe, there is an increasing demand for healthcare IT solutions and extensive research and development activities is taking place by clinical research and academic institutes for cancer treatment. According to Cancer Research UK, in 2014, 356,860 new cases of cancer were reported, including 579 cases of bone cancer.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the high prevalence of chronic disease such as cancer, obesity, diabetes and other. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand for technologically advanced medical devices and accessories such as gene chips for research activities. Availability of highly qualified medical professionals dedicated to research in biological systems is also a contributing factor. The various other factors affecting the growth of the market in Asia Pacific are rising geriatric population, demand for advanced therapies, government initiatives, and increasing public awareness about various diseases and the available treatments.

Additionally, healthcare spending in Asia Pacific expanded in 2016 due to an extension of state healthcare programs, and the increasing affluence of the population. Organization for Economic Co-operation and Development (ECOD) stated that growth in India will remain high at 7.3% in 2017.

The Middle East & Africa also show a steady rise in the market owing to low technological penetration and increasing awareness about cancer treatment. In the Middle East & Africa, Middle East captures the largest market share for biological medicines owing to the availability of better healthcare infrastructure and wide scope for research.

Key Players in the Global Biological computers Market

Some of the key players in this market are Microsoft (U.S.), IBM (U.S.), Thermofisher Scientific (U.S.), Illumina, Inc. (U.S.), IndieBio (U.S.), Emulate Inc. (U.S.), and others. Key players manufactruing DNA or gene chips are Sequenom Inc., Merck KGaA (U.S.), Macrogen Corp (Republic of Korea), Bioneer Corporation (Republic of Korea), Biometrix Technology Inc (U.S.), Wafergen Biosystems Inc. (U.S.), and Eurofins Genomics India Pvt Ltd. (India).

Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/biological-computers-market-5067

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Brain Dead Diagnosis and Treatment Market 2019–By Identifying the Key Market Segments and Key players holding market share

Market Scenario

The increasing incidence of accidents and brain injury is leading to shift from treatment to oragn donation procedures are some factors responsible for the growth of the global brain dead diagnosis and treatment market.

A brain-dead patient is supposed to have no clinical evidence of brain function upon physical examination. The examination exhibits no cranial nerve reflexes and no response to pain. The reflexes include no spontaneous respirations, oculocephalic reflex, pupillary response (fixed pupils), corneal reflex, and no response to the caloric reflex test. According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

It is of utmost important to distinguish brain death and other states that may be difficult to differentiate from brain death, such as alcohol intoxication, chronic vegetative states, barbiturate overdose, hypoglycemia, hypothermia, coma, and sedative overdose. Few comatose patients can recover to pre-coma level of functioning, and some patients with severe irreversible neurological dysfunction will nonetheless retain some lower brain functions, such as spontaneous respiration, despite the losses of both cortex and brain stem functionality in case of anencephaly. However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.

The global market of brain dead diagnosis and treatment is expected to grow at a CAGR of approximately 7% during the forecast period 2017-2023.

Intended Audience

Brain Dead Diagnosis and Treatment Suppliers
Brain Dead Diagnosis and Treatment Manufacturers
Research and Development (R&D) Companies
Medical Research Laboratories
Academic Medical Institutes and Universities

Segmentation

The brain dead diagnosis and treatment market is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of diagnosis, it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG), radionuclide angiography, cerebral arteriography, nuclear brain scanning, transcranial doppler ultrasonography

On the basis of treatment, it is segmented into medical treatment, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.

Key Players in the Global Brain Dead Diagnosis and Treatment Market

Some of key the players in the Global Brain dead diagnosis and Treatment Market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others

Regional Analysis

The global brain dead diagnosis and treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America dominated the global brain dead diagnosis and treatment market owing to the increasing healthcare expenditure. In the United States, if the patient is at or near death, the hospital must notify a transplant organization of the person's details and maintain the patient while the patient is being evaluated for suitability as a donor. The patient is kept on ventilator support until the organs have been surgically removed. Furthermore, increased R&D activities and the concentration of major companies have fueled the growth of the market in this region.

Europe holds the second position in the global brain dead diagnosis & treatment market owing to the government support for research & development and availability of funds for research. For instace, in countries such as Spain, Finland, Poland, Wales, Portugal, and France, everyone is automatically an organ donor after diagnosis of death on legally accepted criteria, although some jurisdictions such as Singapore, Spain, Wales, France, Czech Republic and Portugal allow opting out of the system. Elsewhere, consent from family members or next-of-kin may be mandatory for organ donation.

Asia Pacific is the fastest growing brain dead diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries such as New Zealand, Australia, drivers are asked upon application if they wish to be registered as an organ donor are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.

Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/brain-dead-diagnosis-and-treatment-market-4997

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Gestational Trophoblastic Disease Market 2019–By Identifying the Key Market Segments and Key players holding market share

Market Scenario:

The global gestational trophoblastic disease market is expected to grow significantly at a healthy CAGR during the forecast period from 2018 to 2023. Gestational trophoblastic disease (GTD) comprises a group of interrelated ailments that arise from the placental trophoblastic tissue. This can occur after normal or abnormal fertilization and is characterized by a distinct tumor marker, β-subunit of human chorionic gonadotrophin (β HCG).

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6558

Increase in risk factors affecting this spectrum of disease is expected to drive the growth of the market. These risk factors include high maternal age, the rise in ectopic pregnancies and excessive smoking. According to the American Lung Association, cigarette smoking kills an estimated 201,770 women annually in the US. Also, the increase in innovations in the field of oncology in anticipated to contribute significantly to the growth in this market. For instance, as on 11th October 2018, Bristol-Myers Squibb Company and Compugen Ltd. announced a clinical collaboration to evaluate therapeutic regimen in advanced solid tumors. Compugen Ltd., being a therapeutic discovery company, consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Moreover, high risk of recurrence of the tumors, even after single or multi-agent chemotherapy and difficulty in diagnosing the types of hydatidiform moles may hamper the market growth. Also, mismanagement of the disease with unclear or no guidelines in different regions may curb the growth of gestational trophoblastic disease during the assessment period. Some of the forms of the gestational trophoblastic disease start to show symptoms only after it reaches stage III. At this stage, it might have already spread to other parts of the body. According to the American Society of Clinical Oncology (ASCO), about 35% of women with placental-site trophoblastic tumor have had the cancer spread before it was diagnosed.

Competitive Landscape:

Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Pfizer Inc., Bristol-Myers Squibb Company, Antares Pharma, Mylan N.V., Novartis AG, BP Pharmaceuticals Laboratories Company, Fresenius Kabi AG, Accord Healthcare, Inc., Eli Lilly and Company, Sanofi, Bayer AG, Amgen Inc. and Merck are some of the key players in the global gestational trophoblastic disease market.

Segmentation:The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.

The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.

The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease, whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.

The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.

The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.

The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.

The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.

Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.

On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.

Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/gestational-trophoblastic-disease-market-6558

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com